Secondary Logo

Institutional members access full text with Ovid®

Commentary

Aripiprazole

The Second Wave of the Second-generation Antipsychotics

KAHN, DAVID A., MD

Journal of Psychiatric Practice®: March 2019 - Volume 25 - Issue 2 - p 146–147
doi: 10.1097/PRA.0000000000000373
CLINICAL CASE DISCUSSIONS
Buy

Three cases are presented describing unique clinical responses to aripiprazole in comparison with other second-generation antipsychotics taken by each patient. One case involved an adverse reaction of problem gambling behavior, the second an enhanced antipsychotic response in delusional disorder, and the third a reversal of weight gain that occurred while the patient continued taking olanzapine. Aripiprazole was the first of a subgroup of atypical antipsychotics that are mixed agonists and antagonists of dopamine, likely contributing to unusual responses in some patients.

KAHN: Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY

The author declares no conflicts of interest.

Please send correspondence to: David A. Kahn, MD, Department of Psychiatry, Columbia University College of Physicians and Surgeons, 601 West 168th Street, Unit 31, New York, NY 10032 (e-mail: dak1@columbia.edu).

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.